Co-Diagnostics up 59% premarket on availability of COVID-19 test

Co-Diagnostics (NASDAQ:CODX) is poised to add to its torrid pace with its announcement that its coronavirus virus test kits are now available for purchase by CLIA-certified laboratories who have yet to complete their Emergency Use Authorization submissions with the FDA. Previously, labs had to wait for agency sign-off before ordering.

Shares up 59% premarket on robust volume. If the premarket price holds, shares will be up 20-fold since mid-January.

COVID-19-related tickers and premarket movement: AHPI (+21%), CEMI (+10%), IBIO (+42%), LAKE (+11%), VXRT (+15%), INO (+5%), NVAX (+9%), BCRX (+3%), COCP (+24%), MRNA (+3%), NNVC (+5%), REGN (+3%), GILD (+1%), JNJ (-1%), OPGN (+15%)

https://seekingalpha.com/news/3547333-co-diagnostics-up-59-premarket-on-availability-of-covidminus-19-test